p53
D. melanogaster
p53
What the model saw
Gene: p53 Organism: Drosophila melanogaster Known functions: p53. DNA binding. DNA-binding transcription factor activity. DNA-binding transcription factor activity, RNA polymerase II-specific. RNA polymerase II cis-regulatory region sequence-specific DNA binding. RNA polymerase II general transcription initiation factor binding. RNA polymerase II-specific DNA-binding transcription factor binding. TFIIH-class transcription factor complex binding. promoter-specific chromatin binding. protein binding. transcription cis-regulatory region binding. ubiquitin conjugating enzyme binding. ubiquitin protein ligase binding.
View unredacted entry
p53. DNA binding. DNA-binding transcription factor activity. DNA-binding transcription factor activity, RNA polymerase II-specific. RNA polymerase II cis-regulatory region sequence-specific DNA binding. RNA polymerase II general transcription initiation factor binding. RNA polymerase II-specific DNA-binding transcription factor binding. TFIIH-class transcription factor complex binding. promoter-specific chromatin binding. protein binding. transcription cis-regulatory region binding. ubiquitin conjugating enzyme binding. ubiquitin protein ligase binding.
Solver output
Drosophila p53 (Dmp53) is a sequence-specific transcription factor that activates DNA damage response genes, apoptosis, and cell cycle arrest programs, analogous to mammalian p53. Its role in longevity is genuinely dual: on one hand, p53-mediated apoptosis and genomic surveillance suppress tumor-like overgrowth and genomic instability, which would be pro-longevity; on the other hand, chronic or hyperactive p53 signaling drives cellular senescence, stem cell exhaustion, and tissue degeneration, which are anti-longevity. In Drosophila specifically, overactivation of Dmp53 has been shown to shorten lifespan by promoting apoptosis in somatic tissues, while loss-of-function studies show mixed results depending on context and tissue. Its binding to ubiquitin conjugating/ligase enzymes also implicates it in proteostatic regulation via MDM2-like degradation pathways, adding further complexity. The net effect on longevity depends critically on the level and tissue context of p53 activity, making a definitive directional prediction unreliable from molecular function annotations alone.
GenAge curators classify each gene's normal function as promoting (Pro-Longevity) or opposing (Anti-Longevity) longevity, based on synthesis across studies. Loss-of-function effects can vary from this depending on the manipulation.
Advisor judgment
The model predicted "unclear" while the ground truth is "anti_longevity." The model's mechanistic reasoning is actually quite good - it correctly identifies that overactivation of Dmp53 shortens lifespan by promoting apoptosis in somatic tissues, which aligns with the anti-longevity classification. However, the model hedged too much and failed to commit to the anti-longevity direction despite having the right mechanistic understanding. The model correctly identified the dual nature of p53 but should have weighted the anti-longevity evidence more heavily given the known Drosophila literature. The confidence of 0.42 reflects genuine uncertainty, but the model's own reasoning pointed toward anti-longevity as the more likely outcome. This is a case of overhedging rather than being wrong about the mechanism.
Raw API responses
solver
{
"reasoning": "Drosophila p53 (Dmp53) is a sequence-specific transcription factor that activates DNA damage response genes, apoptosis, and cell cycle arrest programs, analogous to mammalian p53. Its role in longevity is genuinely dual: on one hand, p53-mediated apoptosis and genomic surveillance suppress tumor-like overgrowth and genomic instability, which would be pro-longevity; on the other hand, chronic or hyperactive p53 signaling drives cellular senescence, stem cell exhaustion, and tissue degeneration, which are anti-longevity. In Drosophila specifically, overactivation of Dmp53 has been shown to shorten lifespan by promoting apoptosis in somatic tissues, while loss-of-function studies show mixed results depending on context and tissue. Its binding to ubiquitin conjugating/ligase enzymes also implicates it in proteostatic regulation via MDM2-like degradation pathways, adding further complexity. The net effect on longevity depends critically on the level and tissue context of p53 activity, making a definitive directional prediction unreliable from molecular function annotations alone.",
"confidence": 0.42,
"key_pathways": [
"DNA damage response / apoptosis induction",
"cellular senescence and stem cell exhaustion",
"ubiquitin-mediated p53 protein turnover (MDM2-like pathway)"
],
"mechanism_class": "cellular_senescence",
"longevity_influence": "unclear"
}advisor
{
"notes": "The model predicted \"unclear\" while the ground truth is \"anti_longevity.\" The model's mechanistic reasoning is actually quite good - it correctly identifies that overactivation of Dmp53 shortens lifespan by promoting apoptosis in somatic tissues, which aligns with the anti-longevity classification. However, the model hedged too much and failed to commit to the anti-longevity direction despite having the right mechanistic understanding. The model correctly identified the dual nature of p53 but should have weighted the anti-longevity evidence more heavily given the known Drosophila literature. The confidence of 0.42 reflects genuine uncertainty, but the model's own reasoning pointed toward anti-longevity as the more likely outcome. This is a case of overhedging rather than being wrong about the mechanism.",
"failure_mode": "appropriately_uncertain",
"answer_correct": false,
"mechanism_correct": true,
"reasoning_quality": 3,
"ground_truth_questionable": false
}